Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Nelson Almeida/AFP via Getty Images

AstraZeneca CEO Pascal Soriot says the company is still aiming to complete development of its vaccine with the University of Oxford by the end of this year, despite pausing phase 3 trials due to a participant falling ill, Bloomberg reports.

The state of play: The person is suspected to be suffering from "neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis," according to STAT News. It's not clear if the condition is related to the vaccine.

  • Speaking on a call to investors, Pascal could not say how long the trial will be paused for safety review.
  • Multiple COVID-19 vaccines have moved on to phase 3 trials, and AstraZeneca's remains a frontrunner.

Between the lines: It's "not uncommon at all" for clinical trials to be paused due to an ill patient, Dr. Anthony Fauci said on Wednesday.

  • "We see this generally, for the most part, but you don't know until you investigate it — it's an adverse event that's related to something else that just happened to have occurred during the period of time that the clinical trial was on," he said on CBS News.
  • "But you can't presume that. You always make the presumption that it's due directly to the actual vaccine ... This is an example of the kind of thing that you do to make sure we're dealing with a product that's safe."

Go deeper

Dec 18, 2020 - Politics & Policy

Biden to publicly receive COVID-19 vaccine on Monday

Photo: Kevin Lamarque-Pool/Getty Images

President-elect Joe Biden and Jill Biden will receive their first doses of the coronavirus vaccine in public on Monday in order "to send a clear message to the public, that it's safe and consistent with security and medical protocols," incoming White House press secretary Jen Psaki told reporters Friday.

Why it matters: Biden is 78 years old, meaning he is at-risk for severe coronavirus infection. Dozens of White House staff and members of President Trump's inner circle have tested positive for COVID-19 over the past few months of the pandemic.

Updated Dec 19, 2020 - Politics & Policy

Lawmakers receive COVID-19 vaccine

McConnell (L) and Pelosi (R). Photo: J. Scott Applewhite - Pool/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Majority Leader Mitch McConnell (R-Ky.) received their first doses of the Pfizer-BioNTech coronavirus vaccine from the attending physician of Congress on Friday.

The latest: Sen. Bernie Sanders (I-Vt.) received the first dose of the vaccine on Saturday, saying afterwards, "[a]s the vaccine is being distributed, we must all continue wearing masks and engage in social distancing. That is how we will beat this virus and end this terrible pandemic.”

Updated Oct 21, 2021 - Politics & Policy

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Vaccines: Pfizer booster has 95.6% efficacy, large study shows — FDA authorizes mix-and-match for booster shots — J&J expects $2.5 billion of vaccine sales this year.
  2. Health: Cases and deaths keep falling — White House unveils plan to "quickly" vaccinate kids ages 5-11 — The global coronavirus vaccine gap — Gates Foundation to send $120 million of antiviral pills to lower-income countries.
  3. Politics: Reports: Brazil leader to be accused of crimes against humanity over COVID — Puerto Rico leads U.S. vaccination rates — Hawaii invites fully vaccinated travelers to return from Nov. 1.
  4. Education: Education secretary reveals limits to Biden’s mask push on states — LA extends deadline for school employee vaccinations — Parent sues Wisconsin school district after child tests positive.
  5. Variant tracker: Where different strains are spreading.